Trials / Conditions / Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary Hemorrhagic Telangiectasia (HHT)

12 registered clinical trials studyying Hereditary Hemorrhagic Telangiectasia (HHT) — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia NCT07255846	Terremoto Biosciences Inc.	Phase 1
Enrolling By Invitation	Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in NCT07445347	Poitiers University Hospital	—
Completed	Description of the Impact of Symptoms on Quality of Life in HHT Disease: DISQUO NCT07191639	Hospices Civils de Lyon	—
Active Not Recruiting	Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment St NCT07018401	Massachusetts General Hospital	—
Active Not Recruiting	Assess Safety and Efficacy of VAD044 in HHT Patients NCT05406362	Vaderis Therapeutics AG	Phase 1 / Phase 2
Completed	Doxycycline for Hereditary Hemorrhagic Telangiectasia NCT03397004	Unity Health Toronto	Phase 2
Completed	Graded TTCE for Post-Embolization PAVM Monitoring NCT02936349	University of Pennsylvania	—
Completed	Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT) NCT02638012	Unity Health Toronto	N/A
Completed	Frequency of Common Medical Conditions in People With and Without HHT NCT02464644	Imperial College London	N/A
Withdrawn	Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia NCT01406639	University of California, San Diego	Phase 1
Completed	Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telan NCT01402531	University of California, San Diego	Phase 2
Completed	Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangie NCT01397695	University of California, San Diego	Phase 2